Invention Grant
- Patent Title: Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
-
Application No.: US15534527Application Date: 2015-11-12
-
Publication No.: US10532052B2Publication Date: 2020-01-14
- Inventor: Friedhelm Bladt , Manja Friese-Hamim
- Applicant: Merck Patent GmbH
- Applicant Address: DE Darmstadt
- Assignee: Merck Patent GmbH
- Current Assignee: Merck Patent GmbH
- Current Assignee Address: DE Darmstadt
- Agency: Millen White Zelano and Branigan, PC
- Agent Csaba Henter
- Priority: EP14004200 20141212
- International Application: PCT/EP2015/002265 WO 20151112
- International Announcement: WO2016/091346 WO 20160616
- Main IPC: A61K31/506
- IPC: A61K31/506
Abstract:
A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
Public/Granted literature
Information query
IPC分类:
